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Since the introduction of the IGHV gene somatic hypermuta-
tion (SHM) status as prognostic marker in chronic lympho-
cytic leukaemia (CLL) patients in the two 1999 landmark
publications from the Stevenson and Chiorazzi groups
(Damle et al., 1999; Hamblin et al., 1999), its value has been
consistently confirmed in virtually all CLL cohorts analysed
thus far. To distinguish good from poor prognostic CLL sub-
groups, a threshold of 98% identity to the closest germline
(=unrearranged) immunoglobulin heavy variable (IGHV)
gene was introduced. CLL cases showing a clonally rear-
ranged IGHV gene with <98% identity to the closest IGHV
gene (classified as IG-mutated CLL, M-CLL) constitute the
more favourable group, while those with ≥98% identity (un-
mutated CLL, U-CLL) represent the adverse group.
Notably, the 98% threshold is purely mathematical rather
than biological, considering that even a single SHM (repre-
senting far less than the 2% deviation from germline) could
have a major impact on antigen specificity and affinity. Nev-
ertheless, from a haematological perspective, the 98% thresh-
old is useful to define CLL subgroups with statistically
distinct outcomes. That said, the 98% threshold has been
challenged, although the published data are somewhat con-
flicting (Davis et al., 2016; Jain et al., 2018; Morabito et al.,
2018). In particular, the group of so-called borderline CLL
cases (i.e. 97–979% IGHV identity) has raised interpretation
issues as to whether these would be bona fide M-CLL cases
or not (Davis et al., 2016). Reflecting this uncertainty, the
most recent ERIC (European Research Initiative on CLL)
guidelines on IGHV gene SHM status interpretation consider
this borderline group as a category that should be reported
with caution (Rosenquist et al., 2017).
In this issue of the British Journal of Haematology, a ret-
rospective analysis from the Italian CLL group addresses the
prognostic impact of borderline IGHV SHM status (Raponi
et al., 2020). IGHV data from two large cohorts of
untreated CLL patients were updated in line with current
ERIC guidelines (i.e. repeat analysis with an IGHV leader
protocol, if required) and using the latest IMGT (ImMuno-
GeneTics) version for annotation. In doing so, the most
accurate definition of percentage of IGHV gene identity and
SHM determination for the prognostic evaluation could be
achieved, still resulting in almost 10% shifts in categories
(borderline vs. M-CLL vs. U-CLL), highlighting the critical
importance of robust analytical standards. Subsequent eval-
uation showed that the time-to-first treatment (TFT) of
borderline cases appeared very similar to M-CLL but was
clearly different from U-CLL, while the same held true even
in newly diagnosed and Binet stage A CLL, leading the
authors to conclude that borderline cases can be considered
favourable-prognostic, albeit with a single striking exception
represented by stereotyped subset #2. The latter is very rele-
vant, given that the subset #2 is renowned for its adverse
prognosis and is known to be enriched in borderline CLL
cases (Baliakas, 2015). Moreover, it raises the question as to
whether this is restricted to subset #2 or whether other, as
of now non-disclosed, stereotyped subsets with adverse
prognosis might also be over-represented in this borderline
group, which is especially relevant considering emerging
evidence for the existence of ‘satellites’ to subset #2, i.e.
subgroups of cases with similar immunogenetic and clinico-
biological features [Gemenetzi et al. iwCLL (International
Workshop on CLL) 2019]. Hence, arguably, a ‘compart-
mentalised’ approach may assist in cleaning up the border-
line group to enrich for truly indolent cases, eventually
refining risk stratification. Multi-centre studies from collab-
orative groups collecting enough CLL borderline cases
should reveal the impact of more stereotypic subsets being
present in the borderline group. More broadly, these find-
ings emphasise the importance of accurate IGH gene
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sequence analysis and interpretation in CLL, a fact acknowl-
edged by the inclusion of IGHV gene SHM-testing in the
list of mandatory tests for all CLL patients requiring front-
line treatment (Hallek et al., 2018); as well as the recent
decisions/proposals by national CLL study groups [e.g.
FILO (French Innovative Leukemia Organisation), GCLLSG
(German CLL Study Group)] that subset #2 membership
should be used for risk stratification of patients in clinical
trials (Fischer et al., 2016).
Raponi et al. also made another intriguing observation
that perhaps not only the borderline group (970–979%
IGHV identity) is relevant for further consideration, but
equally so the 980–989% IGHV identity group, which is
sometimes also referred to as a borderline group by some
authors. In their experience, this CLL group appears indistin-
guishable from the true borderline group, yet shows a better
TFT than the 99–100% group (Raponi et al., 2020). Even
though this seems to conflict with other published data
(Davis et al., 2016), the observation is interesting and high-
lights the need for further investigation.
Taken together, these considerations elicit the question as
to whether the IGHV gene SHM status should be considered
as a binary or a continuous marker – in other words,
whether using one threshold (98%) is accurate for all situa-
tions or whether, perhaps in context-dependent fashion, this
parameter should be interpreted as a continuous variable
(Jain et al., 2018). This is a most relevant question for CLL
today, for at least two important reasons: i) IGHV gene
SHM status is not only a prognostic factor any more, but
also predictive of responses to individual treatments, and so
the required accuracy for the individual patient is more
demanding; ii) with the introduction of NGS-based strategies
for IGHV SHM analysis, it remains to be determined if cur-
rent thresholds for non-NGS strategies are still valid. Twenty
years after the first description, IGHV SHM analysis is thus
still highly valid, and perhaps more relevant than ever before.
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